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 Abstract  21 
In this study, 90 human breast milk samples collected from Japan, Korea, 22 
and China were analyzed for perfluorooctanoic acid (PFOA) (C8), 23 
perfluorononanoic acid (PFNA) (C9), perfluorodecanoic acid (PFDA) (C10), 24 
perfluoroundecanoic acid (PFUnDA) (C11), perfluorododecanoic acid 25 
(PFDoDA) (C12), and perfluorotridecanoic acid (PFTrDA) (C13). In addition, 26 
infant formulas (n=9) obtained from retail stores in China and Japan were 27 
analyzed. PFOA was the predominant compound and was detected in more 28 
than 60% of samples in all three countries. The PFOA, PFNA, PFDA, and 29 
PFUnDA levels in Japan were significantly higher than those in Korea and 30 
China (p<0.05). The PFTrDA level was highest in Korea (p<0.05). The 31 
median PFOA concentrations were 89 pg mL-1 (48% of total perfluorinated 32 
carboxylic acids (PFCAs) (C8–C13)) in Japan, 62 pg mL-1 (54%) in Korea, and 33 
51 pg mL-1 (61%) in China. The remaining PFCAs (C9–C13) were 95 pg 34 
mL-1 in Japan, 52 pg mL-1 in Korea, and 33 pg mL-1 in China. Among the 35 
long-chain PFCAs, odd-numbered PFCAs were more frequently detected 36 
than even-numbered PFCAs, except for PFDA in Japan. There were no 37 
evident correlations between the mother’s demographic factors and the 38 
PFCA concentrations. PFOA, PFNA, and PFDA were frequently detected in 39 
both Japan and China, but there were no significant differences between the 40 
two countries. The total PFCA concentrations in the infant formulas were 41 
lower than those in the breast milk samples in Japan (p<0.05), but not in 42 
China (p>0.05). In conclusion, various PFCAs were detected in human breast 43 
 milk samples from East Asian countries. Further studies are needed to 44 
evaluate the exposure to long-chain PFCAs and the health risks in infants. 45 
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 1. Introduction 49 
Perfluorinated compounds (PFCs) comprise a large group of man-made 50 
fluorinated organic chemicals. They have been produced since the 1950s and 51 
are used for various industrial and consumer-related applications, such as 52 
food packaging materials, protective coatings for textiles, carpets, papers, 53 
and surfactants (Key et al., 1997). During the last decade, PFCs such as 54 
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) have 55 
been found at considerable levels in various biota samples including the liver 56 
and tissues, and especially human blood and serum, worldwide (Fromme et 57 
al., 2009).  58 
The toxic effects of PFOS and PFOA have been investigated in animal 59 
studies. Prenatal as well as postnatal toxic effects of PFOA and PFOS were 60 
observed in rats and mice, including increased liver weights, growth lags, 61 
and delayed development. The reproductive and developmental toxicities of 62 
these chemicals toward humans are of particular concern (Lau et al., 2004). 63 
Several epidemiological investigations have raised concerns regarding the 64 
developmental effects of PFOS and PFOA on children, such as low birth 65 
weights (Steenland et al., 2010).  66 
In the Stockholm Convention on Persistent Organic Pollutants, PFOS is 67 
listed in Annex B (Wang et al., 2009). Fluoropolymer manufacturers have 68 
also committed themselves to voluntarily reducing PFOA emissions under a 69 
stewardship program by the US EPA (EPA, 2006). The temporal trends in 70 
serum levels have revealed decreases in the serum levels of both PFOA and 71 
 PFOS in the United States, Norway, and Japan since 2000 (Olsen et al., 72 
2007; Harada and Koizumi, 2009; Haug et al., 2009; Harada et al., 2010). 73 
In contrast to PFOS and PFOA, little information is available for 74 
perfluorinated carboxylic acids (PFCAs) with longer chains than PFOA. The 75 
emissions of perfluorononanoic acid (PFNA) and perfluoroundecanoic acid 76 
(PFUnDA) were 25 and 7 metric tons, respectively, in 2000 (Prevedouros et 77 
al., 2006). A modeling study indicated that these PFCAs could also have been 78 
emitted from precursor compounds, such as fluorotelomer alcohols (FTOHs), 79 
for decades (Van Zelm et al., 2008). Recent evidence suggests that the 80 
toxicological effects of PFCAs are strongly correlated with their chain 81 
lengths and functional groups (Upham et al., 1998; Matsubara et al., 2006; 82 
Wolf et al., 2008; Liao et al., 2009). Therefore, the effects of exposure to 83 
long-chain PFCAs need to be clarified, especially in infants. 84 
Human breast milk and infant formulas are considered to be the main 85 
PFC exposure sources for infants during the lactation period. Indeed, 86 
contamination of PFCs in human breast milk has been reported in various 87 
studies from Asia (So et al., 2006; Tao et al., 2008; Nakata et al., 2009; Liu et 88 
al., 2010; Kim et al., 2011; Liu et al., 2011), the United States (Kuklenyik et 89 
al., 2004; Tao et al., 2008; von Ehrenstein et al., 2009), and Europe (Karrman 90 
et al., 2007; Bernsmann and Furst, 2008). However, the available data for 91 
PFCAs with longer chains than PFNA in human breast milk are limited, 92 
because of the low recoveries of long-chain PFCAs from human breast milk 93 
samples (Karrman et al., 2007). 94 
 The aim of the present study was to investigate the current levels of 95 
long-chain PFCAs in human breast milk in East Asian countries, which were 96 
reported to show increasing trends for long-chain PFCAs in serum (Harada 97 
et al., 2011). Human breast milk samples collected from Japan, Korea, and 98 
China were analyzed for PFOA, PFNA, perfluorodecanoic acid (PFDA), 99 
PFUnDA, perfluorododecanoic acid (PFDoDA), and perfluorotridecanoic acid 100 
(PFTrDA) using an ion-pair extraction method (Hansen et al., 2001) with 101 
modifications. In addition, infant formulas from representative 102 
manufacturers in the Japanese and Chinese markets were analyzed for 103 
comparison with the PFCA concentrations in the breast milk samples from 104 
the same regions. 105 
 106 
2. Methods and Materials  107 
2.1. Study population and sample information 108 
To evaluate the geographical differences in the PFCA levels in human 109 
breast milk, we selected 30 samples each from Japan, Korea, and China that 110 
were stored in the Human Specimen Bank of Kyoto University (Koizumi et 111 
al., 2005; Koizumi et al., 2009). For infant formulas, we obtained five 112 
products from five different companies in the Japanese market and four 113 
products from four different companies in the Chinese market. The main 114 
ingredients of these infant formulas were cow milk, cow milk-related 115 
products (milk whey protein, lactose, and casein), and edible oils (palm olein 116 
and soybean oil). A summary of the sample information is provided in Table 117 
 1. 118 
Written informed consent was obtained from all the participants. The 119 
research protocol for the present study was reviewed and approved by the 120 
Ethics Committee of the Kyoto University Graduate School of Medicine on 14 121 
November 2003 (E25).  122 
 123 
2.2. Standards and reagents 124 
Analytical standards for the PFCAs, 13C4-labeled PFOA and 13C5-labeled 125 
PFNA, were obtained from Wellington Laboratories (PFC-MXA, MPFOA, 126 
and MPFNA; Guelph, Ontario, Canada).  127 
Methanol, acetone, dichloromethane (DCM), and hexane (purity: >99%, 128 
pesticide analysis grade) were obtained from Kanto Chemicals (Tokyo, 129 
Japan). Ethyl acetate (pesticide analysis grade), methyl t-butyl ether (MTBE, 130 
pesticide analysis grade), tetrabutylammonium hydrogen sulfate (TBA), 131 
sodium carbonate, sodium bicarbonate, and benzyl bromide were purchased 132 
from Wako Pure Chemicals (Osaka, Japan). Ultrapure water (Milli-Q™ 133 
Reference; Millipore, Billerica, MA) was used for all solutions. MTBE, DCM, 134 
and hexane were prefiltered through silica gel (Presep-C silica gel; Wako 135 
Pure Chemicals). Methanol, ethyl acetate, and acetone were distilled before 136 
use. Milli-Q water was filtered through an Oasis WAX column (Waters, 137 
Milford, MA). 138 
 139 
 2.3. Sample preparation and extraction 140 
Frozen human breast milk samples were thawed and returned to room 141 
temperature before extraction. A liquid–liquid and solid–phase extraction 142 
method was used to extract the PFCAs in the samples. Aliquots of breast 143 
milk (2 mL) together with an internal standard (13C4-PFOA, 1 ng) were 144 
placed in 15-mL polypropylene sample tubes. Next, 2 mL of 0.5 M TBA/0.25 145 
M sodium carbonate buffer (pH adjusted to 10 using NaOH) and 2 mL of 146 
methanol were added to the samples and vortexed for 15 s. After addition of 147 
3 mL of MTBE, the samples were mixed again and centrifuged at 10,000 rpm 148 
for 5 min. The supernatants were separated into new glass tubes. Another 3 149 
mL of MTBE was added and the extraction was performed again. The 150 
combined sample extracts were dried under a gentle stream of nitrogen. 151 
Subsequently, each extract was dissolved in 4 mL of 1:1 MTBE/DCM and 152 
loaded onto a Presep-C silica gel column preconditioned with 45 mL of 153 
methanol and 4 mL of 1:1 MTBE/DCM on a vacuum manifold. The silica gel 154 
column was washed with 10 mL of hexane and 30 mL of ethyl acetate that 155 
had been prefiltered through another Presep-C silica gel column. The target 156 
fraction was eluted using 12 mL of acetone that had been prefiltered through 157 
an alumina column (Sep-Pak plus alumina N; Waters). The eluate was dried 158 
under a gentle stream of dry nitrogen. The residue was then redissolved in 159 
100 µL of 0.1 M benzyl bromide/acetone solution and derivatized at 60 °C for 160 
1 h. No further clean-up was conducted. 161 
The infant formulas were dissolved in Milli-Q water according to the 162 
 guidelines on the packages. Cow milk (4 mL), Milli-Q water (2 mL, 163 
procedural blank), and infant formulas (2 mL) were treated by the same 164 
procedure used for the human breast milk samples． 165 
 166 
2.4. Instrumental analysis 167 
The extracts were analyzed by gas chromatography–mass spectrometry 168 
(Agilent 6890GC/5973MSD; Agilent Technologies Japan Ltd., Tokyo, Japan) 169 
in the electron impact ionization mode. The PFCAs were separated on a 170 
J&W DB-5MS column with a helium carrier gas (1.5 mL min-1). The splitless 171 
injection volume was 2 μL. The oven temperature was 70 °C for 2 min 172 
initially, and then ramped up to 280 °C at 20 °C min-1. The monitored ions 173 
are listed in Table 2. Standard stock solutions (2 μg mL-1) were diluted to 174 
seven working standard solutions (4, 2, 1, 0.8, 0.4, 0.2, and 0.1 ng mL-1) by 175 
serial dilutions in acetone. All the standard solutions were stored in a 176 
refrigerator at 4 ± 2 °C for a maximum period of 3 months from the date of 177 
preparation.  178 
The instrumental detection limits (IDLs) were defined as the mass of 179 
analyte producing a peak with a signal–to–noise ratio of 3, and ranged from 180 
0.5 pg (PFUnDA, PFDoDA, and PFTrDA) to 0.2 pg (other PFCAs). 181 
 182 
2.5. Quality assurance 183 
We used Milli-Q water as the procedural blank control. The average blank 184 
values (n=6) were 20.5 pg mL-1 (PFOA), 5.2 pg mL-1 (PFNA), and 7.1 pg mL-1 185 
 (PFDA). In the case of blank levels, the mean blank signal was subtracted 186 
from the calculated sample concentration only if the calculated sample 187 
concentration was three times higher than the blank concentration. If no 188 
signal was detected in the blank samples, the method detection limits 189 
(MDLs) were based on the IDLs and 2-mL milk samples. Using this method, 190 
we established that the MDLs ranged from 40 to 10 pg mL-1 (Table 2).  191 
13C4-PFOA was used as an internal standard for the PFCAs. 13C5-PFNA 192 
was used to monitor the recovery of the internal standard. The recoveries of 193 
the PFCAs were examined by spiking 500 pg of each standard compound into 194 
cow milk. The mean recoveries of PFOA, PFNA, PFDA, PFUnDA, PFDoDA, 195 
and PFTrDA were 104%, 84%, 109%, 95%, 92%, and 97%, respectively. 196 
Typical chromatograms of PFCAs obtained in this study are shown in 197 
Supplemental figure 1. 198 
For quality assurance and quality control of our analytical methods and 199 
procedures in the analysis of PFCAs in the breast milk samples, we 200 
measured PFCAs in standard reference materials from the National 201 
Institute of Standards and Technology (Table 2). The PFCA values were 202 
comparable to those reported previously (Keller et al., 2010). 203 
 204 
2.6. Statistical analysis 205 
We calculated the percentages of detection of the PFCAs in each country, 206 
and determined the range, median, mean, standard deviation, geometric 207 
mean, and 90th percentile concentration. Concentrations below the MDL 208 
 were replaced by half of the MDL for statistical analyses. Nonparametric 209 
statistical tests were applied to assess the statistical significance of 210 
differences between values. The Steel–Dwass test was used to compare 211 
differences in the PFCA concentrations among different countries after the 212 
Kruskal–Wallis test. Spearman’s rank correlation analysis was used to 213 
examine the relationships between the PFCA levels and the mother’s age 214 
and child’s birth weight. The Mann–Whitney test was used to examine the 215 
relationships between the PFCA levels and alcohol drinking and cigarette 216 
smoking. The level of statistical significance was set at p<0.05. A factor 217 
analysis was used to elucidate the number of potential factors of sources. The 218 
analyses were conducted via a correlation matrix. Eigenvectors were 219 
employed for the analysis when the eigenvalues were greater than 1. 220 
Normalized varimax rotation was applied to these eigenvectors. The 221 
statistical analyses were carried out using the software JMP® 4 (SAS 222 
Institute Inc., Cary, NC) or R Ver. 2.12.1. (Ihaka and Gentleman, 1996) for 223 
the Steel–Dwass test. 224 
 225 
3. Results 226 
3.1. PFCA concentrations in breast milk in Japan, Korea, and China 227 
The demographic characteristics of the participants are shown in Table 1. 228 
The participants in Korea were, on average, about 3 years older than those 229 
in Japan and China. The descriptive statistical data are summarized in 230 
Table 3. PFOA was the predominant compound and was detected in more 231 
 than 60% of samples in all three Asian countries. The median concentration 232 
of PFOA ranged from 51 pg mL-1 in China to 89 pg mL-1 in Japan. The PFOA 233 
levels in Japan were significantly higher than those in Korea and China 234 
(p<0.05, Steel–Dwass test). 235 
 PFNA and PFUnDA were detected at comparable rates to PFOA in the 236 
three countries. The levels of PFNA and PFUnDA were higher in Japan than 237 
in Korea and China (p<0.05, Steel–Dwass test). PFDA was frequently 238 
detected in Japan (67%), but rarely detected in Korea (13%) and China (13%). 239 
In Korea, half of the milk samples contained detectable levels of PFTrDA, 240 
which was the highest among the three countries (p<0.05, Steel–Dwass test). 241 
PFDoDA was detected in few samples in the three Asian countries and there 242 
were no significant differences (p>0.05). Regarding the total PFCAs in the 243 
milk samples, PFOA accounted for 48%, 54%, and 61% in Japan, Korea, and 244 
China, respectively. Among the long-chain PFCAs, odd-numbered PFCAs 245 
were more frequently detected than even-numbered PFCAs, except for PFDA 246 
in Japan. 247 
PFOA was only significantly correlated with PFNA (ρ coefficient: >0.4) 248 
(Supplemental table 1). There were also significant correlations between 249 
PFNA and PFUnDA, PFDA and PFUnDA, and PFUnDA and PFTrDA (ρ 250 
coefficients: >0.4). In general, the PFCA concentrations showed strong 251 
correlations between PFCAs of similar (i.e. adjacent) chain lengths. 252 
The factor analysis revealed that two potential factors, F1 and F2, 253 
accounted for 43.3% and 19.0% of the total variance (with eigenvalues of >1), 254 
 respectively (Table 4). After varimax rotation, F1 indicated higher 255 
eigenvectors for PFOA, PFNA, PFDA, and PFUnDA, while F2 had positive 256 
eigenvectors for PFUnDA and PFTrDA. The mean factor scores of each 257 
sampling site are also shown in Table 4. Although the F1 score was higher in 258 
Kyoto than in the other two sites (p<0.05, Steel–Dwass test), there were no 259 
significant differences in the F2 scores among all the sampling sites (p>0.05, 260 
Kruskal–Wallis test). 261 
 262 
3.2. PFCA concentrations in commercially available infant formulas in Japan 263 
and China 264 
The PFCA concentrations in the infant formulas are shown in Table 5. 265 
PFOA, PFNA, and PFDA were frequently detected in both Japan and China, 266 
but there were no significant differences between the two countries. 267 
PFUnDA was detected at 40.7 pg mL-1 in one sample in Japan. PFDoDA and 268 
PFTrDA were not detected in any of the formula samples. Compared with the 269 
breast milk samples, the PFOA levels were 4-fold and 2-fold lower in the 270 
formula samples in Japan and China, respectively. The total PFCA 271 
concentrations in the infant formulas were lower than those in the breast 272 
milk samples in Japan (p<0.05, Kruskal–Wallis test), but not in China 273 
(p>0.05, Kruskal–Wallis test). 274 
 275 
3.3. Relationships between the PFCA levels and the participants' 276 
characteristics 277 
 To evaluate the influence of the participants’ characteristics on the PFCA 278 
concentrations in the human breast milk samples, Spearman’s correlation 279 
analyses were performed (Supplemental table 2). PFDoDA was positively 280 
correlated with the mother’s age in Korea (p<0.05) and PFNA was negatively 281 
correlated the mother’s age in China (p<0.05). However, these correlations 282 
were not consistent among the three countries. In several epidemiological 283 
studies (Steenland et al., 2010), the PFC concentrations in the cord blood or 284 
maternal pregnancy serum were reported to be associated with the child 285 
birth weight. In our study subjects, the correlations between the PFCA 286 
concentrations and the child birth weights were not significant. The lactation 287 
period was also examined for correlations with PFCAs in the milk samples. 288 
PFDA was correlated with the lactation period in Japan (p<0.05), but not in 289 
Korea. Among the PFCAs, there were no clear trends in the correlation 290 
coefficients. Although consumption of fish was one of the sources of exposure 291 
to PFCAs, no significant associations were observed between the PFCA 292 
levels in the milk samples and the fish intake (p>0.05). Non-smoking 293 
mothers in Japan had relatively higher PFCAs levels than other mothers, 294 
but the difference was not significant (p>0.05). The PFCA levels in the milk 295 
samples were compared between non-drinking mothers and other mothers. 296 
The PFTrDA and PFNA levels were lower in non-drinking mothers in Japan 297 
and Korea (p<0.05, Mann–Whitney test). 298 
 299 
3.4. Daily intake estimation and hazard assessment for infants  300 
 The tolerable daily intake (TDI) for PFOA was established to be 1500 ng kg 301 
body weight-1 d-1 by the Scientific Panel on Contaminants in the Food Chain 302 
requested by the European Food Safety Authority in 2008 (). The average 303 
breast milk consumption rate and body weight for 1-year-old infants were 304 
assumed to be 600 g d-1 and 7.3 kg, respectively (Schecter, 1994). Based on 305 
these assumptions, the daily intakes of PFCAs by 1-year-old infants were 306 
estimated (Supplemental table 3). For the infant formulas, the calculated 307 
mean levels were only 0.1–0.2% of the TDI. Meanwhile, the calculated levels 308 
for the human breast milk samples (means: 0.3–0.5% of the TDI; 90th 309 
percentiles: 0.6–0.9% of the TDI) were higher than those for the infant 310 
formulas. As of 2011, there is no established TDI for PFCAs that are longer 311 
than PFOA. 312 
 313 
4. Discussion 314 
In the present study, we first demonstrated contamination of human 315 
breast milk with PFDoDA and PFTrDA in Asian countries. Simultaneously, 316 
we confirmed similar long-chain PFCA profiles in East Asian breast milk 317 
samples, as previously reported (Liu et al., 2010; Kim et al., 2011; Liu et al., 318 
2011). A characteristic PFCA composition was observed for PFUnDA and 319 
PFTrDA (both odd-numbered PFCAs) with residual PFDoDA and PFDA 320 
(both even-numbered PFCAs). These findings indicated that odd-numbered 321 
PFCAs predominated over even-numbered PFCAs in East Asian breast milk 322 
samples. The PFCAs with longer chains than PFOA reached 47% of the total 323 
 PFCAs for the average of the three countries. This finding suggests that 324 
infants are exposed to not only classical PFOA but also long-chain PFCAs in 325 
East Asia. Indeed, a factor analysis demonstrated two potential factors, F1 326 
and F2, as sources of PFCAs. F1 had loading on medium-chain PFCAs, of 327 
which the factor score was significantly higher in Kyoto than in Beijing or 328 
Seoul. Kyoto is located in the Hanshin area, where there is a large emission 329 
source of PFOA and its related by-products (Niisoe et al., 2010). Thus, F1 330 
may represent a local emission source of PFCAs. On the other hand, F2 had 331 
strong associations with long-chain PFCAs. The factor scores for F2 in the 332 
three large cities did not differ, suggesting that there are similar sources of 333 
long-chain PFCAs (>C10) in the three counties. Therefore, PFCA (C10–C13) 334 
exposure through the breast milk is likely to commonly occur in East Asian 335 
countries. We are the first to document this possibility. 336 
The sources of long-chain PFCAs are still unknown. Odd-numbered PFCAs 337 
predominated in the PFCAs in this study. As previously reported (Harada et 338 
al., 2011), odd-numbered PFCAs also predominated in serum samples 339 
collected from Asian women. A review by Prevedouros et al. (2006) indicated 340 
that odd-numbered PFCAs have been manufactured in Japan via oxidation 341 
of fluorotelomer olefins. Industrial application of these odd-numbered PFCAs 342 
might contribute to the pattern of PFCAs in breast milk samples collected 343 
from East Asian women. Although FTOHs are possible precursors of PFCAs, 344 
biodegradation of FTOHs preferentially yields even-numbered PFCAs 345 
(Fasanoa et al., 2009). Therefore, FTOHs are unlikely to be the main 346 
 exposure source for Asian populations. Further investigations into the 347 
sources and exposure routes are needed to predict the future trajectory of 348 
these PFCA levels. 349 
Although data concerning the PFC levels in human breast milk are not as 350 
abundant as those in blood samples, we can still find several reports for 351 
PFCs in human breast milk from Asia, the United States, and Europe. The 352 
related data are summarized in Table 6. In Japan, the PFOA levels in three 353 
regions were comparable (Tao et al., 2008; Nakata et al., 2009). In Korea, 354 
PFOA had a higher value in the present study compared with earlier 355 
research in Seoul (Kim et al., 2011) (mean: 63.8 vs. 41 pg mL-1, range: 356 
14.7–172.1 vs. 21–77 pg mL-1). This increase may be consistent with the 357 
increasing trend in the PFOA level in serum samples by 1.27-fold from 2000 358 
to 2007 in Korea (Harada et al., 2010). 359 
In China, the concentrations of PFOA in Zhoushan ranged from 47 to 210 360 
pg mL-1 (So et al., 2006) and in 12 different provinces of China, the mean 361 
PFOA level was 116 pg mL-1 (Liu et al., 2010). The PFOA levels showed large 362 
variations within China, although the other PFCAs were comparable among 363 
two previous studies and this study. In Southeast Asian developing countries, 364 
most of the milk samples did not contain detectable PFCAs (Tao et al., 2008), 365 
which might result from differences in industrialization. In the United 366 
States and European countries, PFOA and PFNA were detected in human 367 
breast milk samples, but long-chain PFCAs were not observed (Kuklenyik et 368 
al., 2004; Karrman et al., 2007; Bernsmann and Furst, 2008; Tao et al., 2008; 369 
 Volkel et al., 2008; Karrman et al., 2010; Llorca et al., 2010). The occurrence 370 
of long-chain PFCAs in East Asian countries is likely to be a fingerprint of 371 
the sources of exposure. 372 
Infant formulas were also evaluated in this study. The compositions of 373 
PFCAs in the infant formulas were different from those in the breast milk 374 
samples. In Japan, the levels of PFCAs in the infant formulas were lower 375 
than those in the breast milk samples. These findings probably reflect 376 
differences in the bioaccumulation potential between humans and cows. 377 
In our study, we found no evident relationships between the mother’s 378 
characteristics and the PFCA concentrations. Although there were 379 
statistically significant differences for some of the PFCAs, no consistent 380 
trends were observed among the three countries.  381 
The estimated daily intakes of PFOA were much lower than the TDI in 382 
this study. These observations may indicate that the health risks for PFOA 383 
intake from breast milk and infant formulas are limited. However, infants 384 
have different susceptibilities to adults with regard to their dynamic growth 385 
and developmental processes (Sly et al., 2008). In addition, the toxicokinetics 386 
and toxicities of long-chain PFCAs are still unclear, although these PFCAs 387 
comprised 48% of the total PFCAs in this study. These uncertainties 388 
necessitate more comprehensive toxicological studies on long-chain PFCAs, 389 
including PFOA. 390 
The limitations of this study are the sample sizes and the sample selection 391 
method. It should be noted that these findings were based on a relatively 392 
 small number of non-randomly selected volunteer samples. Moreover, the 393 
sampling times for the Chinese donors were uncertain, although it is known 394 
that the profiles of chemicals may change during the lactation period. 395 
Considering these limitations, a future extended study is required for 396 
confirmation of these findings, 397 
In conclusion, various PFCAs were detected in human breast milk samples 398 
from East Asian countries. Further studies are needed to evaluate the 399 
exposure to long-chain PFCAs and the health risks in infants. 400 
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Supplemental figure 1.  545 
Typical chromatograms of PFCAs obtained in this study. 546 
Table 1
Study areas and sample information.
a. Human milk
Sampling site n Year Age (year)a (range) Parity(n ) Smokingbc Drinkingc Lactation period (week)a
Japan
Kyoto 30 2010 27.8±3.4 (21-33) 1(30) Ex (7), non (23) Ex(18), non(12) 3.0±0.5
Korea
Seoul 30 2010 30.9±2.3 (26-36) 1(22), 2(8) Ex (3), non (27) Curr(3), ex(2), non(25) 1.6±1.1
China
Beijing 30 2008, 2009 27.0±1.7 (23-30) 1(30) Non (30) Curr(2), ex(27), non(1) NA
b. Infant formula
Sampling site n Year Targeted infant age 
(month)
Japan
Kyoto 5 2010 0-12
China
Beijing 4 2010 0-12
aData are presented as the mean ± standard deviation.
cCurr: current; ex: experienced; non: never.
bIncluding second-hand tobacco smoke.
Table 2
Recoveries and detection limits for the PFCA analyses in human serum samples.
Compound Quantification Instrument detection Blank (pg mL-1) Method detection Recovery and (reproducibility) Standard Reference Material 1954c
 (confirmation)  limita (pg) range (mean)  limitb (pg mL-1) mean percentage (SD) (n =9) This study (pg g- U. Torontod (pg g-1) Env. Canadad (pg g-1)
PFOA 504 (485) 0.2 12.0-32.1(20.5) 40 104(14) 117 149 116
13C4 PFOA 508 (489) - - - 99(12) - - -
PFNA 554 (535) 0.2 <5-14.7(5.2) 10 84 (44) 24 22 <16
13C5 PFNA 559 (540) - - - - - - -
PFDA 604 (585) 0.2 <5-25.8(7.1) 15 109 (32) 16 14 <6
PFUnDA 654 (635) 0.5 <10 10 95 (45) 12 7 <14
PFDoDA 704 (685) 0.5 <10 10 92 (25) <10 3 <8
PFTrDA 754 (735) 0.5 <10 10 97 (27) <10 - -
aInjection of 2 µL.
cMilk standard reference material from the National Institute of Standards and Technology, 1954.
dAnalyzed by the University of Toronto and Environment Canada (Keller et al., 2010).
bMilk sample of 2 mL (the mean blank signal was subtracted from the calculated sample concentration only if the calculated sample
concentration was three times higher than the blank concentration).
Table 3
Concentrations of PFCAs in breast milk samples.
Sampling Concentration (pg mL-1)
site PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs
Japan n >MDL(%) 28(93.3) 27(90.0) 20(66.7) 28(93.3) 5(16.7) 10(33.3) 30(100.0)
Kyoto Median 89(<40-194)A* 31(<10-72)A* 17(<15-65)A* 35(<10-100)A* <10(<10-29)n.s. <10(<10-91)AB* 184(50.3-413.5)A*
Mean 93.5±43.7 32.1±17.2 21.3±15.0 36.6±21.8 <10 15.2±20.6 194.5±83.6
GM(GSD) 82.7(1.7) 26.5(2.0) 16.9(2.0) 30.4(2.0) <10 <10 176.7(1.6)
P90 173 62 44 65 22 36 315
Korea n >MDL(%) 24(80.0) 20(66.7) 4(13.3) 22(73.3) 4(13.3) 15(50.0) 28(93.3)
Seoul Median 62(<40-173)B* 15(<10-41)B* <15(<15-19)B* 19(<10-51)B* <10(<10-41)n.s. 10(<10-43)A* 114(<10-283.9)B*
Mean 64.5±33.7 14.7±9.3 <15 19.6±13.1 <10 16.8±13.5 118.8±50.9
GM(GSD) 55.5(1.8) 11.9(2.0) <15 15.3(2.2) <10 11.7(2.4) 109.7(1.5)
P90 106 29 15 42 11 40 189
China n >MDL(%) 19(63.3) 21(70.0) 4(13.3) 17(56.7) 3(10.0) 7(23.3) 28(93.3)
Beijing Median 51(<40-122)B* 15(<10-47)B* <15(<15-29)B* 15(<10-47)B* <10(<10-25)n.s. <10(<10-43)B* 84(<10-200.8)B*
Mean 51.6±30.6 15.3±9.6 <15 16.0±12.9 <10 <10 87.8±54.9
GM(GSD) 43.0(1.9) 12.6(2.0) <15 11.7(2.3) <10 <10 68.8(2.2)
P90 103 27 18 42 10 22 164
MDL: method detection limit; GM: geometric mean; GSD: geometric standard deviation; P90: 90th percentile.
*Medians among different sites differ significantly (p <0.05, Steel–Dwass test). For example, the letters A and B indicate that the
corresponding values differ significantly at p <0.05, while A and A or B and B indicate that the corresponding values do not differ
significantly.
Table 4
Factor analysis among PFCAs.
Initial solution Varimax rotated
F1 F2 F1 F2
Eigenvalue 2.60 1.14
Cumulative contribution (%) 43.3 62.3
Eigenvector
PFOA 0.387 -0.511 0.818 -0.135
PFNA 0.472 -0.375 0.857 0.060
PFDA 0.480 -0.020 0.668 0.390
PFUnDA 0.518 0.261 0.563 0.677
PFDoDA 0.114 0.430 -0.086 0.488





*Means among countries differ significantly (p<0.05, Steel–Dwass
test). For example, the letters A and B indicate that the
corresponding values differ significantly at p<0.05, while A and A or
B and B indicate that the corresponding values do not differ
significantly.
Table 5
Concentrations of PFCAs in infant formulas.
Sampling Sample no. Concentration (pg mL-1)a
site PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs
Japan 1 <20 <5 <7 <5 <5 <5 <5
2 35.8 27.0 <7 <5 <5 <5 62.8
3 30.8 8.0 12.1 <5 <5 <5 50.9
4 <20 8.6 11.5 <5 <5 <5 20.1
5 22.5 92.0 19.8 40.7 <5 <5 175.0
Mean±SD 21.8±11.8 27.6±37.2 10.1±6.9 10.1±17.1 <5 <5 66.4±65.6
China 1 35.4 50.4 14.0 <5 <5 <5 99.7
2 <20 15.2 <7 <5 <5 <5 15.2
3 37.1 12.2 12.9 <5 <5 <5 62.2
4 29.9 11.6 13.9 <5 <5 <5 55.4
Mean±SD 28.1±12.4 22.4±18.8 11.1±5.1 <5 <5 <5 61.5±29.3
aA 4-mL aliquot of each infant formula was analyzed.
Table 6
Comparisons of the PFCA concentrations in human breast milk with reported data (pg ml -1).
Country Region Year n PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA Reference
Japan Kyoto 2010 30 Mean 93.5 32.1 21.3 36.6 <10 15.2 This study
Range <40-194 <10-72 <15-65 <10-100 <10-29 <10-91
Hokkaido NA 51 Mean 89 35 Nakata et al., 2009
Range <12-339 <4-150
Ehime 1999 24 Mean 77.7 Tao et al., 2008
Range <42.5-170 <8.82-23.9
Korea Seoul 2010 30 Mean 64.5 14.7 <15 19.6 <10 16.8 This study
Range <40-173 <10-41 <15-19 <10-51 <10-41 <10-43
Mean 41 Kim et al., 2011
Range <43-77 <8.8 <18 <24 <13
China Beijing 2008- 30 Mean 51.6 15.3 <15 16.0 <10 <10 This study
2009 Range <40-122 <10-47 <15-29 <10-47 <10-25 <10-43
Zhoushan 2004 Mean 106.3 18.1 7.2 19.1 So et al., 2006
Range 47-210 6.3-62 3.8-15 7.6-56
12 provinces 2007 1237 Mean 116.0 16.2 9.9 37.6 Liu et al., 2010
Range <14.15-814 6-76 <1.44-63 <1.30-196
 (24 pooled samples) 




40 Range <42.5-89.2 <8.82-10.9 Tao et al., 2008
Cambodia Phnom Penh 2000 24 Range <42.5-132 <8.82-12.3 Tao et al., 2008
Philippines Quezon 2000,
2004
24 Range <42.5-183 <8.82-25.0 Tao et al. , 2008
Malaysia Penang 2003 13 Range <42.5-90.4 <8.82-14.9 Tao et al., 2008
Indonesia Jakarta,
Purwakarta






39 Range <42.5-335 <8.82 Tao et al., 2008
USA Unknown 2003 2 Range <200 Kuklenyik et al., 2004
Massachusetts 2004 45 Mean 43.8 7.26 Tao et al., 2008
Range <30.1-161 <5.2-18.4
Sweden Uppsala 2004 12 Range < 209–492 < 5–20 <8 <5 Kärrman et al., 2007
1996- 9 Range <209 <5-28 <8 <5
2004 (Pooled annual composite milk sample)
Germany NA 2006 38 Range 201-460 Völkel et al., 2008
(Archived samples+19 fresh samples)
North Rhine NA 203 25-610 Bernsmann et al., 2008
Westphalian
Spain Tarragona 2007 10 Range <500 <30 <60 <30 <30 Kärrman et al., 2010





Correlations between PFCAs with different chain lengths.
Combination ρ p  value
PFNA PFOA 0.418 <0.001
PFDA PFOA 0.321 0.002
PFDA PFNA 0.369 <0.001
PFUnDA PFOA 0.359 0.001
PFUnDA PFNA 0.475 <0.001
PFUnDA PFDA 0.422 <0.001
PFDoDA PFOA -0.007 0.945
PFDoDA PFNA 0.010 0.923
PFDoDA PFDA 0.256 0.015
PFDoDA PFUnDA 0.110 0.304
PFTrDA PFOA 0.094 0.377
PFTrDA PFNA 0.082 0.443
PFTrDA PFDA 0.031 0.769
PFTrDA PFUnDA 0.478 <0.001
PFTrDA PFDoDA 0.151 0.156
ρ : Spearman's correlation coefficient.
Supplemental Table 2
Associations between the PFCA concentrations and the participants' characteristics.
Variables PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA
Mother’s age (yr)a
Japan -0.056 0.054 0.014 0.328 0.371 0.384
Korea 0.317 0.092 0.021 0.186 0.385* -0.156
China -0.119 -0.421* 0.197 -0.297 0.051 -0.208
Child birth weight (g)a
Japan -0.104 -0.017 0.101 0.174 -0.017 0.107
Korea -0.058 -0.103 0.043 0.081 -0.081 0.077
China NA NA NA NA NA NA
Lactation period (wk)a
Japan 0.125 0.104 0.474* 0.315 -0.026 -0.225
Korea 0.088 -0.044 0.181 -0.121 -0.193 -0.107
China NA NA NA NA NA NA
Fish intake (g/wk)a
Japan -0.223 -0.173 -0.127 -0.135 0.163 0.161
Korea 0.098 0.026 0.314 0.133 0.072 -0.023
China NA NA NA NA NA NA
Smokingb
Japan Non-smoker (23) 101±45 35±19 24±16 40±24 9±8 17±23
Others (7) 69±28 23±6 12±7 27±11 5±0 8±6
Drinkingb
Japan Non-drinker (12) 96±51 36±16 21±4 30±15 6±5 6±3
Others (18) 92±39 30±18 22±4 41±25 9±8 21±25*
Korea Non-drinker (25) 61±27 13±8 8±4 19±13 7±7 15±13
Others (5) 83±58 26±10** 7±0 22±14 6±3 25±13
aFor continuous variables, Spearman's correlation analysis was used for evaluations with the PFCA concentrations.
*p <0.05, **p <0.005.
bFor categorical variables, the means were compared between two groups by the Mann–Whitney test.
Supplemental Table 3
Daily intake estimations and hazard assessment for 1-year-old infants.
Sampling Estimated Intakea  (ng kg body weight-1 d-1)
site PFOA PFNA PFDA PFUnDA PFDoDA PFTrDA ΣPFCAs
Japan Breast milk Mean 7.7 2.6 1.8 3.0 0.4 1.2 16.0
Kyoto ％b 0.5% - - - - - -
P90 14.2 5.1 3.6 5.3 1.8 3.0 25.9
％b 0.9% - - - - - -
Infant formula Mean 1.8 2.3 0.8 0.8 0.2 0.2 5.5
％b 0.1% - - - - - -
Korea Breast milk Mean 5.3 1.2 0.6 1.6 0.4 1.4 9.8
Seoul ％b 0.4% - - - - - -
P90 8.7 2.4 1.2 3.5 0.9 3.3 15.5
％b 0.6% - - - - - -
China Breast milk Mean 4.2 1.3 0.6 1.3 0.4 0.4 7.2
Beijing ％b 0.3% - - - - - -
P90 8.5 2.2 1.5 3.5 0.8 1.8 13.5
％b 0.6% - - - - - -
Infant formula Mean 2.3 1.8 0.9 0.2 0.2 0.2 5.1
％b 0.2% - - - - - -
P90: 90th percentile.
aThe breast milk consumption rate and body weight for 1-year-old infants were assumed to be 600 g d-1 and 7.3 kg, respectively
(Schecter, 1994).
bPercent of the tolerable daily intake (1500 ng kg body weight-1 d-1) for PFOA by the Scientific Panel on Contaminants in the Food
Chain requested by the European Food Safety Authority in 2008 (EFSA, 2009).
